Dr. Reddy’s, Alvotech to co-develop, market biosimilar of Merck’s cancer drug Keytruda  

Dr. Reddy’s headquarters in Hyderabad
| Photo Credit: Arrangement

Pharma main Dr. Reddy’s Laboratories and Nasdaq-listed international biotech agency Alvotech will co-develop, manufacture and commercialise a biosimilar candidate to Merck’s cancer drug Keytruda (pembrolizumab) for international markets.

They will probably be collectively chargeable for creating and manufacturing the biosimilar candidate and sharing prices in addition to the tasks. “Subject to certain exceptions, each party will have the right to commercialise the product globally,” Dr. Reddy’s and Alvotech stated on Thursday (June 5, 2025) in a joint assertion saying the signing of a licence settlement.

The collaboration will mix their confirmed capabilities in biosimilars thus dashing up the event course of and lengthening international attain for the biosimilar candidate. A registered trademark of Merck Sharp & Dohme Corp, Keytruda is indicated for the remedy of quite a few cancer sorts. In 2024, the worldwide gross sales of Keytruda have been $29.5 billion.

Oncology high focus remedy

“Oncology has been a top focus therapy area for us and this collaboration will further enhance our capabilities in oncology, as pembrolizumab currently represents one of the most critical therapies in immuno-oncology,” Dr. Reddy’s CEO Erez Israeli stated.

Alvotech chairman and CEO Robert Wessman stated “we are pleased to enter into this collaboration for pembrolizumab with Dr. Reddy’s. This agreement demonstrates Alvotech’s ability to leverage its dedicated R&D and manufacturing platform for biosimilars, accelerating the expansion of our pipeline by pursuing growing global markets.”